Sign in

    Eric Musonza

    Director at UBS

    Eric Musonza is a Director at UBS, focusing on equity research with specialization in Asian markets and covering prominent listed companies such as AEM Holdings, CapitaLand Investment, ComfortDelGro Corporation, and First Resources. His research has consistently provided accurate forecasts, with recent earnings reports and sector outlooks offering actionable insights to investors. Musonza's career includes prior analytical experience at major financial institutions before joining UBS, contributing to detailed sector coverage and driving research publications as of at least August 2025. He holds advanced professional credentials relevant to his role in equity research analysis, underscoring his expertise and regulatory compliance in the financial industry.

    Eric Musonza's questions to Kura Oncology (KURA) leadership

    Eric Musonza's questions to Kura Oncology (KURA) leadership • Q2 2025

    Question

    Eric Musonza, on for David Day, asked for more details on how Kyowa Kirin's sales force will aid the commercial launch and how Kura plans to compete with or leapfrog Janssen's Phase 3 trial in frontline AML.

    Answer

    CCO Brian Powl explained that Kyowa Kirin's team has significant account overlap and will partner with Kura's sales force to provide broader and deeper physician reach. CEO Dr. Troy Wilson addressed the competition by noting Janssen has only initiated one of two planned trials, and Kura is confident it can compete effectively on global enrollment for its COMET-seventeen trials due to overwhelming investigator enthusiasm.

    Ask Fintool Equity Research AI